Table 5.
Cardiovascular profile of t drugs used for the management of COVID-19. Only drugs with “most beneficial” effect on mortality or mechanical ventilation, duration of ventilation, length of hospital stay, or time to resolution of symptoms (as compared to the standard of care) were selected based on the updated living systematic review [1], last access 4 June 2021.
| Drug | QT prolongation */arrhythmia | Myo-pericarditis | MACE | VTE |
|---|---|---|---|---|
| JAK inhibitors | ||||
| Remdesivir | § | |||
| Dexamethasone | ||||
| Colchicine | # | |||
| IL6 inhibitors | ||||
| Favipiravir |
* crediblemeds.org (accessed 4 June 2021); § bradycardia; # potential reduction in atrial fibrillation; VTE: venous thromboembolism; MACE: major adverse cardiovascular events. Please note that the definition of this composite endpoint may vary among studies, but usually includes cardiovascular death, myocardial infarction, ischemic stroke; GREY BOX: unknown effect (no dedicated study performed); WHITE BOX: no effect (in a dedicated study); YELLOW BOX: unclear effect; RED BOX: negative effect (increased risk); and GREEN BOX: positive effect (reduced risk).